G30.0
Conditions
Interventions
Group 1: Subjective and objective healthy subjects with inconspicuous neuropsychological testing
Baseline and followup after 12 months: neuropsychological examination,
PET / CT,
MRI
Group 2: Subjects
Sponsors
Universitätsklinikum Köln Klinik und Poliklinik für Nuklearmedizin
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Principal inclusion criteria HC Group 1. Age > 50 years 2. Subjectively unimpaired cognitive performance 3. Cognitive testing within age norm 4. Unimpaired in activities of daily living 5. Clinical Dementia Rating (CDR): 0 SCD Group 1. Age > 50 years 2. Subjective decline in cognitive performance as reported by the subject 3. Cognitive testing within age norm 4. Unimpaired in activities of daily living 5. Clinical Dementia Rating (CDR): 0 MCI Group 1. Age > 50 years 2. Fulfils criteria of amnestic type of MCI: 1,5 standard deviations below age norm in VLMT. 3. Unimpaired in activities of daily living (Bayer ADL = 5) 4. Clinical Dementia Rating (CDR) of 0.5 DAT Group 1 Age > 50 years 2 Dementia according to ICD-10-criteria with impairment in activities of daily living. 3 Diagnosis of probable dementia of the Alzheimer type according to NINCDS-ADRDA- criteria 4 Clinical Dementia Rating (CDR) of =2
Exclusion criteria
Exclusion criteria: Exclusion HC Group 1. Any radiation exposure in the recent 10 years for scientific or therapy purposes SCD Group 1. Any radiation exposure in the recent 10 years for scientific or therapy purposes MCI Group 1. Fulfils criteria for a dementia (ICD-10-criteria). 2. Other disorders potentially responsible for cognitive decline (e.g. cerebrovascular disorder, Parkinson’s disease) DAT Group 1. Fulfils criteria for other forms of dementia than of the Alzheimer’s type 2. Other disorders potentially responsible for cognitive decline (e.g. cerebrovascular disorder, Parkinson’s disease)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary end points •Extent of amyloid-pathology in the brain cross-sectionally and change of it longitudinally •Functional connectivity (brain network function) •Structural connectivity (brain network integrity) •Interaction between tau- and amyloid-pathology and network function and integrity •Cognitive decline •Neuronal activitation (fMRI activation study) | — |
Primary
| Measure | Time frame |
|---|---|
| Primary trial objective: 1. To document the presence/location of tau-pathology cross-sectionally and longitudinally in early stages of Alzheimer’s disease 2. To evaluate if tau-pathology expands along specific functional networks of the brain over time 3. To investigate if expansion of tau-pathology leads to progressive dysfunction of affected functional brain networks. 4. To explore the association between cerebral tau-pathology and cognitive decline. 5. To explore how amyloid-pathology and tau-pathology are associated with each other Study end points:Primary end points: •Extent of tau-pathology in the brain cross-sectionally and change of it longitudinally | — |
Countries
Germany
Contacts
Public ContactSimone Stockter
Klinik und Poliklinik für Nuklearmedizin
Outcome results
None listed